secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucira Health, Inc. (—)
CIK:        0001652724
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001193125-23-050739
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucira Health gets FDA EUA for first at-home COVID-19 & flu test; Nasdaq delisting set for March 6
--------------------------------------------------------------------------------

- FDA granted EUA for Lucira COVID-19 & Flu Home Test, first OTC at-home test for flu and combo COVID-19/flu.
- Test is molecular (NAAT), delivers results in 30 minutes from one nasal swab; similar performance to lab PCR.
- Nasdaq notified delisting due to Chapter 11 filing; trading suspended at opening on March 6, 2023; company will not appeal.
- Company produced inventory for autumn 2022 launch but could not bridge authorization cycle; now seeking strategic or financial partner.
- Bankruptcy court approved first-day motions on Feb 24 to continue ordinary operations during Chapter 11 case.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652724/000119312523050739/0001193125-23-050739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652724/000119312523050739/d455868d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-050739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer